ST-101 is under clinical development by Sapience Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ST-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ST-101 is under development for the treatment of hematologic malignancies including acute myeloid leukemia, solid tumors including glioma, melanoma, cutaneous melanoma, breast cancer, castration-resistant prostate cancer, locally advanced/metastatic breast cancer, lung cancer, medulloblastoma, triple negative breast cancer (TNBC), hepatocellular carcinoma, esophageal cancer, uveal melanoma and pediatric neuro-oncology such as glioblastoma multiforme and neuroblastoma. The therapeutic candidate is a synthetic peptide designed to contain a cell-penetrating domain and a dominant-negative form of the human transcription factor ATF5. It acts by targeting CCAAT/enhancer binding protein beta (C/EBPB).
Sapience Therapeutics overview
Sapience Therapeutics is a pharmaceutical and healthcare company. It focuses on developing novel therapeutics for major medical needs with special emphasis on high mortality cancers. The company develops products such as ST101, ß-Catenin Antagonist, cJun Antagonist, FoxP3 Antagonist, cMyc Antagonist and others. Sapience Therapeutics ST101 products are used in the treatment of breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML. In addition, the company works in partnership with universities to develop pipeline products for the treatment of GBM and cancer. Sapience Therapeutics is headquartered in Harrison, New York, the US.
For a complete picture of ST-101’s drug-specific PTSR and LoA scores, buy the report here.